Finance ❯Investments
Liver Disease Cost Savings Pharmaceuticals Liver Diseases Drug Pricing Mergers and Acquisitions Corporate Finance Drug Development Drug Efficacy Revenue Growth
The deal, which could reach $2 billion with milestones, positions GSK to target unmet needs in liver disease with a planned 2029 launch.
